DOI QR코드

DOI QR Code

Optimizing Heart Failure Management: A Review of the Clinical Pharmacist Integration to the Multidisciplinary Health Care Team

  • Esteban Zavaleta-Monestel (Pharmacy Department, Hospital Clinica Biblica) ;
  • Sebastian Arguedas-Chacon (Pharmacy Department, Hospital Clinica Biblica) ;
  • Alonso Quiros-Romero (Pharmacy Department, Hospital Clinica Biblica) ;
  • Jose Miguel Chaverri-Fernandez (Faculty of Pharmacy, University of Costa Rica) ;
  • Bruno Serrano-Arias (Pharmacy Department, Hospital Clinica Biblica) ;
  • Jose Pablo Diaz-Madriz (Pharmacy Department, Hospital Clinica Biblica) ;
  • Jonathan Garcia-Montero (Pharmacy Department, Hospital Clinica Biblica) ;
  • Mario Osvaldo Speranza-Sanchez (Heart Failure Program, Hospital Clinica Biblica)
  • Received : 2023.04.18
  • Accepted : 2023.10.23
  • Published : 2024.01.31

Abstract

Heart failure (HF) stands as a prevalent chronic ailment, imposing a substantial burden on global healthcare systems due to recurrent hospitalizations, intricate management, persistent symptoms, and polypharmacy challenges. The augmentation of patient safety and treatment efficacy across various care stages, facilitated by a multidisciplinary HF team inclusive of a clinical pharmacist, emerges as paramount. Evidence underscores that the collaborative engagement of a physician and a clinical pharmacist engenders proficient and secure management, forestalling avoidable adversities stemming from drug reactions and prescription inaccuracies. This synergistic approach tailors treatments optimally to individual patients. Post-discharge, the vulnerability of HF patients to re-hospitalization looms large, historically holding sway as the foremost cause of 30-day readmissions. Diverse strategies have been instituted to fortify patient well-being, leading to the formulation of specialized transitional care programs that shepherd patients effectively from hospital to outpatient settings. These initiatives have demonstrably curtailed readmission rates. This review outlines a spectrum of roles assumed by clinical pharmacists within the healthcare cohort, spanning inpatient care, transitional phases, and outpatient services. Moreover, it traverses a compendium of studies spotlighting the affirmative impact instigated by integrating clinical pharmacists into these fields.

Keywords

References

  1. Ponikowski P, Anker SD, AlHabib KF, et al. Heart Failure Preventing Disease and Death Worldwide. Sophia Antipolis: European Society of Cardiology; 2014. 
  2. Aizpuru F, Millan E, Garmendia I, Mateos M, Librero J. Hospitalizations for heart failure: epidemiology and health system burden based on data gathered in routine practice. Med Clinica Practica 2020;3:100140.
  3. Mesquita ET, Jorge AJ, Rabelo LM, Souza CV Jr. Understanding hospitalization in patients with heart failure. Int J Cardiovasc Sci 2017;30:81-90.
  4. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272-87.
  5. Riello RJ III. Heart failure with reduced ejection fraction. In: Gale SM, ed. PSAP 2022 Book - Cardiology [Internet]. Lenexa: American College of Clinical Pharmacy; 2022 [cited 2023 April 15]. Available from: https://www.accp.com/docs/bookstore/psap/p2022b1_sample.pdf. 
  6. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020;22:1342-56.
  7. Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res 2021;128:1421-34.
  8. Park JJ, Lee CJ, Park SJ, et al. Heart failure statistics in Korea, 2020: a report from the Korean Society of Heart Failure. Int J Heart Fail 2021;3:224-36.
  9. Osenenko KM, Kuti E, Deighton AM, Pimple P, Szabo SM. Burden of hospitalization for heart failure in the United States: a systematic literature review. J Manag Care Spec Pharm 2022;28:157-67.
  10. European Heart Network. Heart Failure and Cardiovascular Diseases - A European Heart Network Paper. Brussels: European Heart Network; 2019. 
  11. Lee H, Oh SH, Cho H, Cho HJ, Kang HY. Prevalence and socioeconomic burden of heart failure in an aging society of South Korea. BMC Cardiovasc Disord 2016;16:215.
  12. Riley JP, Masters J. Practical multidisciplinary approaches to heart failure management for improved patient outcome. Eur Heart J Suppl 2016;18:G43-52.
  13. Morton G, Masters J, Cowburn PJ. Multidisciplinary team approach to heart failure management. Heart 2018;104:1376-82.
  14. de Araujo BC, de Melo RC, de Bortoli MC, Bonfim JR, Toma TS. How to prevent or reduce prescribing errors: an evidence brief for policy. Front Pharmacol 2019;10:439.
  15. Neu R, Leonard MA, Dehoorne ML, Scalia SJ, Kale-Pradhan PB, Giuliano CA. Impact of pharmacist involvement in heart failure transition of care. Ann Pharmacother 2020;54:239-46.
  16. Shah SP, Dixit NM, Mendoza K, et al. Integration of clinical pharmacists into a heart failure clinic within a safety-net hospital. J Am Pharm Assoc (2003) 2022;62:575-579.e2.
  17. Heart Online. Adverse drug reactions and heart failure. Sydney: National Heart Foundation of Australia; 2014. 
  18. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895-1032.
  19. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382:1883-93.
  20. Sizar O, Podder V, Talati R. Empagliflozin. Treasure Island: StatPearls Publishing; 2023. 
  21. Food and Drug Administration. Highlights of Prescribing Information: Dapagliflozin. Silver Spring: Food and Drug Administration; 2021. 
  22. Bazroon AA, Alrashidi NF. Bisoprolol [Internet]. Treasure Island: StatPearl Publications; 2022 [cited 2023 April 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551623/. 
  23. Food and Drug Administration. Highlights of Prescribing Information: Coreg (Carvedilol) [Internet]. Silver Spring: Food and Drug Administration; 1995 [cited 2023 April 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf. 
  24. Food and Drug Administration. Metoprolol Succinate [Internet]. Silver Spring: Food and Drug Administration; 2006 [cited 2023 April 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019962s032lbl.pdf. 
  25. Patibandla S, Heaton J, Kyaw H. Spironolactone. Treasure Island: StatPearls Publishing; 2022.
  26. Sharma A, Verma S, Bhatt DL, et al. Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care? JACC Basic Transl Sci 2022;7:504-17.
  27. Stough WG, Patterson JH. Role and value of clinical pharmacy in heart failure management. Clin Pharmacol Ther 2017;102:209-12.
  28. Unverzagt S, Meyer G, Mittmann S, Samos FA, Unverzagt M, Prondzinsky R. Improving treatment adherence in heart failure. Dtsch Arztebl Int 2016;113:423-30.
  29. Cheng JW. Current perspectives on the role of the pharmacist in heart failure management. Integr Pharm Res Pract 2018;7:1-11.
  30. Hargraves TL, Bennet AA, Brien JE. Developing an outpatient heart failure pharmacy service. J Pharm Pract Res 2008;38:13-6.
  31. Schumacher PM, Becker N, Tsuyuki RT, et al. The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta-analysis. ESC Heart Fail 2021;8:3566-76.
  32. Davis EM, Packard KA, Jackevicius CA. The pharmacist role in predicting and improving medication adherence in heart failure patients. J Manag Care Spec Pharm 2014;20:741-55.
  33. Page RL 2nd, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation 2016;134:e32-69.
  34. Hargraves TL, Bennett AA, Brien JE. Evaluating outpatient pharmacy services: a literature review of specialist heart failure services. Int J Pharm Pract 2010;14:3-9.
  35. Wang C, Lin Z, Miao D, et al. Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study. ESC Heart Fail 2023;10:1961-71.
  36. Speranza-Sanchez M, Zavaleta-Monestel E, Sancho-Zumbado S, Arguedas-Chacon S, Quiros-Romero A. From end-of-life care to improved quality of life and better prognosis by using vericiguat: a case report from Costa Rica. Cureus 2023;15:e39570.
  37. Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA 2015;314:2251-62.
  38. Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study. Arch Intern Med 1999;159:1939-45.
  39. Omboni S, Caserini M. Effectiveness of pharmacist's intervention in the management of cardiovascular diseases. Open Heart 2018;5:e000687.
  40. Lynch KA, Ganz DA, Saliba D, Chang DS, de Peralta SS. Improving heart failure care and guideline-directed medical therapy through proactive remote patient monitoring-home telehealth and pharmacy integration. BMJ Open Qual 2022;11:e001901.
  41. Lugo Zamora IL, Lloyd C, Lorenzo-Castro S, Mussenden C, Hale G. Utilizing pharmacist-led telehealth services in ambulatory patients with heart failure. Innov Pharm 2023;14:12.
  42. Mohammad RA, Betthauser KD, Korona RB, et al. Clinical pharmacist services within intensive care unit recovery clinics: an opinion of the critical care practice and research network of the American College of Clinical Pharmacy. JACCP J Am Coll Clin Pharm. 2020;3:1369-79.
  43. Rommers MK, Teepe-Twiss IM, Guchelaar HJ. Preventing adverse drug events in hospital practice: an overview. Pharmacoepidemiol Drug Saf 2007;16:1129-35.
  44. Gabay M, Spencer SH. Drug interactions: scientific and clinical principles. In: Beckett RD, ed. PSAP 2021 Book 3 - Chronic Conditions and Public Health PSAP [Internet]. Lenexa: American College of Clinical Pharmacy; 2021 [cited 2023 May 29]. Available from: https://www.accp.com/docs/bookstore/psap/p2021b3_sample.pdf. 
  45. American College of Clinical Pharmacy. Comprehensive medication management in team-based care [Internet]. Lenexa: American College of Clinical Pharmacy; [cited 2023 May 30]. Available from: https://www.pcpcc.org/sites/default/files/event-attachments/CMM%20Brief.pdf. 
  46. Luisetto M. Intensive care units (ICU): the clinical pharmacist role to improve clinical outcomes and reduce mortality rate - an undeniable function. J Clin Intensive Care Med 2017;2:49-56.
  47. Anderson SL, Marrs JC. A review of the role of the pharmacist in heart failure transition of care. Adv Ther 2018;35:311-23.
  48. Guerrero KS, Puls SE, Andrew DA. Transition of care and the impact on the environment care. J Nurs Educ Pract 2014;4:30-6.
  49. Layman SN, Elliott WV, Regen SM, Keough LA. Implementation of a pharmacist-led transitional care clinic. Am J Health Syst Pharm 2020;77:966-71.
  50. Garcia CG. A literature review of heart failure transitional care interventions. Am J Accountable Care 2017;5:21-5. 
  51. Baecker A, Meyers M, Koyama S, et al. Evaluation of a transitional care program after hospitalization for heart failure in an integrated health care system. JAMA Netw Open 2020;3:e2027410.
  52. Mai Ba H, Son YJ, Lee K, Kim BH. Transitional care interventions for patients with heart failure: an integrative review. Int J Environ Res Public Health 2020;17:2925.
  53. Albert NM, Barnason S, Deswal A, et al. Transitions of care in heart failure: a scientific statement from the American Heart Association. Circ Heart Fail 2015;8:384-409.
  54. Amabile CM, Spencer AP. Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med 2004;164:709-20.
  55. Sorensen A. An evaluation of the impact of clinical pharmacists on care transitions in a non-integrated healthcare system [dissertation]. Los Angeles: University of California, Los Angeles; 2018.